Relevant bibliographies by topics / Polycystic ovary syndrome. eng

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Polycystic ovary syndrome. eng'

Author: Grafiati
Published: 4 June 2021
Last updated: 6 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Polycystic ovary syndrome. eng.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Polycystic ovary syndrome. eng"

1

Spinedi, Eduardo, and Daniel P. Cardinali. "The Polycystic Ovary Syndrome and the Metabolic Syndrome: A Possible Chronobiotic-Cytoprotective Adjuvant Therapy." International Journal of Endocrinology 2018 (July 25, 2018): 1–12. http://dx.doi.org/10.1155/2018/1349868.

Full text
Abstract:
Polycystic ovary syndrome is a highly frequent reproductive-endocrine disorder affecting up to 8–10% of women worldwide at reproductive age. Although its etiology is not fully understood, evidence suggests that insulin resistance, with or without compensatory hyperinsulinemia, and hyperandrogenism are very common features of the polycystic ovary syndrome phenotype. Dysfunctional white adipose tissue has been identified as a major contributing factor for insulin resistance in polycystic ovary syndrome. Environmental (e.g., chronodisruption) and genetic/epigenetic factors may also play relevant roles in syndrome development. Overweight and/or obesity are very common in women with polycystic ovary syndrome, thus suggesting that some polycystic ovary syndrome and metabolic syndrome female phenotypes share common characteristics. Sleep disturbances have been reported to double in women with PCOS and obstructive sleep apnea is a common feature in polycystic ovary syndrome patients. Maturation of the luteinizing hormone-releasing hormone secretion pattern in girls in puberty is closely related to changes in the sleep-wake cycle and could have relevance in the pathogenesis of polycystic ovary syndrome. This review article focuses on two main issues in the polycystic ovary syndrome-metabolic syndrome phenotype development: (a) the impact of androgen excess on white adipose tissue function and (b) the possible efficacy of adjuvant melatonin therapy to improve the chronobiologic profile in polycystic ovary syndrome-metabolic syndrome individuals. Genetic variants in melatonin receptor have been linked to increased risk of developing polycystic ovary syndrome, to impairments in insulin secretion, and to increased fasting glucose levels. Melatonin therapy may protect against several metabolic syndrome comorbidities in polycystic ovary syndrome and could be applied from the initial phases of patients’ treatment.
APA, Harvard, Vancouver, ISO, and other styles
2

Jasti, Prathima, and Andrea Dunaif. "Reproduction and Metabolism: Insights from Polycystic Ovary Syndrome." Endocrinology and Metabolism 27, no. 3 (2012): 180. http://dx.doi.org/10.3803/enm.2012.27.3.180.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Oguz, Seda Hanife, and Bulent Okan Yildiz. "An Update on Contraception in Polycystic Ovary Syndrome." Endocrinology and Metabolism 36, no. 2 (April 30, 2021): 296–311. http://dx.doi.org/10.3803/enm.2021.958.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Popova, P. V., I. V. Gorelova, and E. N. Grineva. "Polycystic ovary syndrome and cardiovascular risk." "Arterial’naya Gipertenziya" ("Arterial Hypertension") 24, no. 6 (January 26, 2019): 654–65. http://dx.doi.org/10.18705/1607-419x-2018-24-6-654-665.

Full text
Abstract:
Polycystic ovary syndrome (PCOS) is a common endocrine disease in women of reproductive age. In addition to hyperandrogenism, impaired ovulation and fertility, PCOS is associated with an increased detection of cardiovascular risk factors such as obesity, insulin resistance, impaired glucose tolerance, type 2 diabetes mellitus, arterial hypertension, and obstructive sleep apnea. The initial stages of the atherosclerotic process are also well documented in women with PCOS. However, data from prospective studies on the end points of cardiovascular morbidity and mortality are scarce and controversial. Perhaps this is due to the fact that PCOS is a heterogeneous group of endocrine, metabolic and reproductive disorders, and different authors consider various combinations of these disorders as the syndrome. Different phenotypes of PCOS may be associated with different cardiovascular risk. Women with a “complete” phenotype (a combination of all three PCOS diagnostic criteria) and with the predominant hyperandrogenism have higher risk. According to a number of studies, obesity affects more than half of women with PCOS and contributes the most to the increased risk of type 2 diabetes mellitus. Despite the weakness of the evidence regarding the association of PCOS with cardiovascular morbidity and mortality, most international organizations recommend active screening for cardiovascular risk factors in women with PCOS.
APA, Harvard, Vancouver, ISO, and other styles
5

Artymuk, N. V., and O. A. Tachkova. "New about the pathogenesis and treatment of polycystic ovary syndrome." Russian Journal of Woman and Child Health 4, no. 1 (2021): 17–22. http://dx.doi.org/10.32364/2618-8430-2021-4-1-17-22.

Full text
Abstract:
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of reproductive age that is characterized by reproductive and metabolic disorders. Mental issues, hypothalamic-pituitary dysfunction, ovarian dysfunction, mitochondrial dysfunction, obesity, and vitamin D deficiency account for infertility in PCOS. This paper reviews recent studies on pathogenesis and treatment approaches to this disease. Recognized therapeutic modalities for PCOS are addressed, i.e., rational diet, combined hormonal contraceptives, ovulation induction using clomiphene citrate and/or metformin, ovarian drilling, assisted reproductive technology, and alternative approaches (e.g., herbal therapy, traditional Chinese medicine, vitamin D, coenzyme Q, salubrinal, and the combination of simvastatin and metformin). Inositols are a promising therapeutic modality that improves menstrual and reproductive function (presumably via their impact on carbonic and lipid metabolism) and the quality of oocytes and embryos. KEYWORDS: polycystic ovary syndrome, pathogenesis, treatment, myo-inositol, ovulation induction, drilling, combined oral contraceptives, lifestyle changes. FOR CITATION: Artymuk N.V., Tachkova O.A. New about the pathogenesis and treatment of polycystic ovary syndrome. Russian Journal of Woman and Child Health. 2021;4(1):17–22. DOI: 10.32364/2618-8430-2021-4-1-17-22.
APA, Harvard, Vancouver, ISO, and other styles
6

Kozica-Olenski, Samantha, Helena Teede, and Rhonda Garad. "Evaluation of a Center of Research Excellence in Polycystic Ovary Syndrome as a Large-Scale Collaborative Research Translation Initiative, Including Evaluating Translation of Guideline Impact." Seminars in Reproductive Medicine 36, no. 01 (January 2018): 042–49. http://dx.doi.org/10.1055/s-0038-1667308.

Full text
Abstract:
AbstractResearch translation and evaluation are often underconsidered in research design and implementation thus limiting research benefit to the end user. In this article, we first describe a best practice approach to evaluation, for a center of research excellence in polycystic ovary syndrome. Within this, we outline a comprehensive research translation program with inbuilt evaluation of the first International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome (2018). We seek to provide a real-world example of comprehensive approaches to evaluation and research translation.
APA, Harvard, Vancouver, ISO, and other styles
7

Li, Xinrong, Beili Lv, Haiyan Wang, and Qiaohong Qian. "Dioscin Ameliorates Polycystic Ovary Syndrome by Inhibiting PI3K/Akt Pathway-Mediated Proliferation and Apoptosis of Ovarian Granulosa Cells." Current Topics in Nutraceutical Research 18, no. 4 (April 15, 2020): 331–36. http://dx.doi.org/10.37290/ctnr2641-452x.18:331-336.

Full text
Abstract:
To understand the mechanism underlying Dioscin inhibition of polycystic ovary syndrome, we have examined its effects on ovarian granulosa cells from letrozole-treated rats. To this end, Western blot was utilized to determine changes in the levels of Bcl-2, cleaved caspase-3, caspase-3, and phosphatidylinositol 3-kinase (PI3K)/protein kinase B pathway after Dioscin treatment in letrozole-treated rats. Dioscin ameliorated polycystic ovary syndrome by reducing the serum level of testosterone and increasing progesterone levels. It also inhibited proliferation and induced apoptosis of ovarian granulosa cells in the rat model by decreasing the level of Bcl-2 and elevating cleaved caspase-3. Western blot analysis revealed that Dioscin suppressed the PI3K/Akt pathway by inhibiting p-AKT/AKT. SC79, a p-AKT/AKT activator, reversed the effects of Dioscin on the proliferation and apoptosis of ovarian granulosa cells. In conclusion, Dioscin might present a novel therapeutic opportunity for patients with polycystic ovary syndrome.
APA, Harvard, Vancouver, ISO, and other styles
8

Lathief, Sanam, and Lubna Pal. "Advances in Treatment Options for Polycystic Ovary Syndrome." US Endocrinology 08, no. 01 (2012): 57. http://dx.doi.org/10.17925/use.2012.08.01.57.

Full text
Abstract:
Polycystic ovary syndrome (PCOS) is the most common endocrinopathy seen in women of reproductive age. Clinical concerns relating to PCOS range from ovulatory infertility and menstrual disorders to risk of diabetes and cardiovascular disease. Hormonal contraceptives have been the mainstay of the management of common PCOS symptoms, such as menstrual irregularity and clinical stigmata of androgen excess (i.e., hirsutism and acne). An appreciation of the relevance of metabolic pathways in the pathophysiology of PCOS is relatively recent, and has translated into an expansion of the therapeutic strategies available for the management of PCOS. Insulin sensitizers were one of the first metabolic modulators to be incorporated in the clinical management paradigm, albeit with mixed results. Recognizing that insulin resistance is central to the pathophysiology of PCOS, newer agents—e.g., thiazolidinediones— followed, with almost comparable efficacy to metformin. Statins and most recently incretins constitute novel therapies with distinct metabolic targets that seem to hold promise in the management of PCOS. In tandem with the expansion in pharmaceuticals, a host of complementary and alternative medical therapies have generated interest for purported promise in the management of PCOS, including vitamin D, acarbose, and myo-inositol. The therapeutic options for managing PCOS-related infertility have also expanded. Clomiphene citrate (CC) has long been the first-line strategy for ovulation induction in the setting of anovulatory infertility; however, aromatase inhibitors are fast gaining acceptance as an ovulation induction strategy, with results comparable or even better than those seen with CC. An increasing level of therapeutic sophistication is reflected in ovarian stimulation protocols judiciously using gonadotropins, gonadotropin-releasing hormone antagonists, the procedure of ovarian drilling, and assisted reproductive technologies within vitrooocyte maturation.
APA, Harvard, Vancouver, ISO, and other styles
9

Sung, Yeon-Ah. "Polycystic Ovary Syndrome in Korean Women: Clinical Characteristics and Diagnostic Criteria." Endocrinology and Metabolism 26, no. 3 (2011): 203. http://dx.doi.org/10.3803/enm.2011.26.3.203.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

ALhabardi, Nadiah A., Osama Al-Wutayd, Khalid M. Eltayieb, Yasir S. Shiha, Ahmad I. AL-Shafei, and Ishag Adam. "Peripheral hematological parameters in women with polycystic ovary syndrome." Journal of International Medical Research 48, no. 9 (September 2020): 030006052095228. http://dx.doi.org/10.1177/0300060520952282.

Full text
Abstract:
Objective There have been few studies on hematological parameters (e.g., hemoglobin, red cell distribution width, white blood cells, and mean platelet volume), and polycystic ovary syndrome (PCOS). This study aimed to compare hematological parameters between women with PCOS and controls. Methods We performed an age-matched case–control study in Faisal bin Mishal Center for Infertility, Buraidah (Kingdom of Saudi Arabia). The cases were women with PCOS and an equal number of healthy women were enrolled as controls. The basic gynecological history was recorded and blood samples were analyzed for blood parameters using an automated hematology analyzer. Results The two groups (60 women in each arm of the study) were similar in age. However, body mass index was significantly higher in women with PCOs compared with controls. There were no significant differences in any of the hematological parameters (hemoglobin, red blood cells, red cell distribution width, white blood cells, platelets, and mean platelet volume) between the two groups. Conclusion There does not appear to be a significant difference in hematological parameters in Saudi women with PCOS and healthy controls. A larger study on this issue is required in the future.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Polycystic ovary syndrome. eng"

1

Cirilo, Priscila Daniele Ramos. "Estudo caso-controle em genes polimórficos das vias esteróide (ER-alfa e ER-beta) e da insulina (INSR, PA-1 e IGF2) na síndrome do ovário policístico /." Botucatu : [s.n.], 2006. http://hdl.handle.net/11449/92464.

Full text
Abstract:
Orientador: Silvia Regina Rogatto
Banca: Ilce Mara de Syllos Colus
Banca: Maria Inês M. Campos Pardini
Resumo: A Síndrome do Ovário Policístico (SOP) é uma doença heterogênea que acomete principalmente mulheres em idade reprodutiva e é caracterizada por alterações clínicas como hiperandrogenismo, anovulação crônica e irregularidades menstruais e metabólicas, como resistência insulínica, obesidade, hiperlipidemia e diabetes mellitus tipo 2. Esta síndrome está associada com o risco aumentado de desenvolvimento de doenças cardiovasculares e tromboembólicas. A síndrome HAIR-AN possui manifestações clínicas semelhantes a SOP, porém por critérios de classificação atuais, compõe diagnóstico diferencial apresentando resistência insulínica severa e hiperandrogenismo. Considerando o fenótipo heterogêneo destas patologias, polimorfismos em genes da via de esteróides e da insulina podem estar associados com hiperandrogenismo e hiperinsulinemia. Foram genotipadas para os polimorfismos nos genes ER-α, ER-β, INSR, IGF2 e PAI-1 41 mulheres com fenótipo SOP, 16 com fenótipo HAIR-AN e 49 controles livres da doença. As regiões polimórficas dos genes ER-α e ER-β foram submetidas a análise automatizada no seqüenciador ABI Prism 377 DNA Sequencer para determinação do número de repetições [TA]n e [CA]n, respectivamente. Os alelos foram classificados em curtos ou longos (ER-α - alelos curtos: <15 e longos ≥15 repetições; ER-β - os alelos curtos: ≤22 e longos >22 repetições). A genotipagem de INSR e IGF2 contendo os polimorfismos C/T e A/G, respectivamente, foi realizada por PCR-RFLP com as enzimas de restrição PmlI e ApaI, respectivamente. Para a observação do polimorfismo 5G/4G do gene PAI-1, utilizou-se a técnica de PCR-SSCP e seqüenciamento direto. Não foram observadas diferenças estatísticas significativas entre os genótipos dos genes ER-α, ER-β, INSR, IGF2 e PAI-1 entre casos e controles... (Resumo completo, clicar acesso eletrônico abaixo)
Abstract: Polycystic Ovary Syndrome (PCOS) is a heterogeneous disorder which is common in reproductive age women and characterized by reproductive and clinical manifestations as hyperandrogenism, anovulatory infertility, increased ovarian secretion, and hyperinsulinaemia, as insulin resistance, type 2 diabetes mellitus, and obesity. The PCOS have been associated with increased risk for development cardiovascular and thromboembolic events. The syndrome of hyperandrogenism, insulin resistance, and acanthosis nigricans (HAIR-AN syndrome) was included in the PCOS subset. However, actually HAIR-AN syndrome shows a differential diagnosis with severe insulin resistance and hyperandrogenism. Genetic polymorphisms in insulin action and steroid pathways genes can be associated with hyperinsulinaemia and hyperandrogenism in PCOS and HAIR-AN patients. The ER-alfa, ER-ß, INSR, IGF2, and PAI-1 genes polymorphisms were evaluated in 41 women with PCOS, 16 women with HAIR-AN, and 49 disease-free control women. The ER-alfa and ER-ß genes polymorphisms were investigated by automated analysis (ABI Prism 377 DNA Sequencer) to determine the [TA]n and [CA]n repeats number, respectively. The alleles were classified as short and long (ER-alfa: <15 and .15 repeats, respectively; and ER-alfa: .22 and >22 repeats, respectively). The INSR and IGF2 genes polymorphisms (C/T and A/G, respectively) were performed by PCR-RFLP methodology using the PmlI and ApaI restriction enzymes, respectively. The PAI-1 gene polymorphisms (5G/4G) were detected by PCR- SSCP and direct sequencing methodologies. No statistical differences were observed between cases and controls for all genes analyzed. However, the comparison between clinical and laboratorial data with the genotypes showed statistical differences (p<0,05). The grouped polymorphisms analysis performed by NeoGene Analysis software defined genotypic classes that can be associated with pathophysiology of the PCOS.
Mestre
APA, Harvard, Vancouver, ISO, and other styles
2

Rehme, Marta Francis Benevides. "O hiperandrogenismo influencia no desenvolvimento de síndrome metabólica em pacientes com síndrome dos ovários policísticos?" Botucatu : [s.n.], 2009. http://hdl.handle.net/11449/106373.

Full text
Abstract:
Orientador: Anaglória Pontes
Banca: Tamara Goldberg
Banca: Marcos Felipe Silva de Sá
Banca: José Alcione Macedo Almeida
Banca: Cleusa Cascaes Dias
Resumo: A síndrome dos ovários policísticos (SOP) afeta 5 a 8% das mulheres no menacme e é caracterizada pela anovulação crônica e hiperandrogenismo. A obesidade central e a resistência insulínica (RI) são freqüentes na SOP e desempenham um papel fundamental na etiopatogenia da síndrome metabólica (SM). O hiperandrogenismo tem sido questionado como um fator importante no desenvolvimento da SM em mulheres com SOP. Verificar se o hiperandrogenismo influencia no desenvolvimento de síndrome metabólica em pacientes com SOP. Foram avaliados retrospectivamente os dados clínicos, bioquímicos e ultrassonográficos de 180 mulheres com SOP diagnosticadas pelos critérios de Rotterdam e de 70 mulheres com obesidade simples. As pacientes com SOP foram classificadas de acordo com o índice de massa corporal (IMC) em SOP não obesas e SOP obesas. As pacientes obesas simples não apresentaram hiperandrogenismo clínico nem bioquímico. O índice de sensibilidade à insulínica (ISI) foi avaliado pelo HOMA-IR e ISI de Matsuda e DeFronzo. A SM foi diagnosticada pelos critérios do NCEP-ATP III com modificações sugeridas pelo consenso de Rotterdam. A média de idade das pacientes foi de 27,3 + 4,7 no grupo das pacientes SOP não obesas; 28,8 + 5,0 nas SOP obesas e 27,4 + 5,2 nas obesas simples (p=0, 0773), e o IMC foi de 25,1+3,0 kg/m2; 37,0+ 5,5 kg/m2 e 36,0+ 4,2 kg/m2 respectivamente (p<0, 001). A prevalência de RI e SM não diferiu entre as pacientes obesas com e sem SOP e foi significativamente maior do que nas SOP não obesas (p<0, 001). Entretanto a prevalência de SM foi maior nas SOP obesas com hiperandrogenismo... (Resumo completo, clicar acesso eletrônico abaixo)
Abstract: Polycystic ovary syndrome (PCOS) affects 5-8% of women at menacme and is characterized by chronic anovulation and hyperandrogenism. Central obesity and insulin resistance (IR) are frequent in PCOS and play a leading role in the etiopathogeny of metabolic syndrome (MS). Hyperandrogenism has been suggested as an important factor in the development of MS in women with PCOS. To determine whether hyperandrogenism influences the development of metabolic syndrome in patients with PCOS. Clinical, biochemical and ultrasonographic data on 180 women with PCOS, as diagnosed by the Rotterdam criteria, and 70 women with simple obesity were retrospectively analyzed. According to body mass index, PCOS patients were classified as nonobese with PCOS and obese with PCOS. No clinical or biochemical hyperandrogenism was observed in patients with simple obesity. Insulin sensitivity indices (ISI) were assessed as proposed by HOMA-IR and ISI (Matsuda and De Fronzo). MS was diagnosed based on NCEP-ATP III criteria with modifications suggested by the Rotterdam consensus. Mean age was 27.3 + 4.7 among non-obese patients with PCOS, 28.8 + 5.0 in obese patients with POS, and 27.4 + 5.2 in those with simple obesity (p=0.0773), while BMI was 25.1+3.0 kg/m2, 37.0+ 5.5 kg/m2 and 36.0+ 4.2 kg/m2, respectively (p<0.001). The prevalence of IR and MS did not differ between obese patients with and without PCOS, and was significantly higher in these patients than in non-obese women with PCOS (p<0.001). The prevalence of MS, however, was higher... (Complete abstract click electronic access below)
Doutor
APA, Harvard, Vancouver, ISO, and other styles
3

Santos, Ana Gabriela Pontes. "Prevalência de resistência à insulina, intolerância à glicose e diabetes mellitus tipo 2 em pacientes com síndrome doa ovários policísticos(SOP) /." Botucatu : [s.n.], 2009. http://hdl.handle.net/11449/99263.

Full text
Abstract:
Orientador: Anaglória Pontes
Banca: Júlio Cesar Rosa e Silva
Banca: Walquíria de Paula Pimenta
Resumo: A síndrome dos ovários policísticos (SOP) é uma endocrinopatia comum em mulheres no menacme, com prevalência variando entre 5 a 10%. Em vários estudos, pacientes com SOP apresentam risco aumentado para o desenvolvimento das anormalidades do metabolismo da glicose. O diabetes mellitus está entre as 10 maiores causas de mortalidade no Brasil decorrente das complicações micro e macrovasculares. Avaliar a prevalência de resistência à insulina (RI), intolerância à glicose (IG) e diabetes mellitus tipo 2 (DM) nas pacientes com diagnóstico de SOP. Foram avaliados retrospectivamente os dados clínicos, bioquímicos e ultra-sonográficos de 247 pacientes com o diagnóstico de SOP. Para a avaliação do grau de RI, utilizou-se um grupo de 101 mulheres com ciclos menstruais regulares sem hiperandrogenismo. O diagnóstico de RI foi obtido utilizando-se os seguintes valores de corte: insulinemia > 12 μIU/ml, HOMA-IR > 2,71, QUICKI < 0,333, ISI < 4,75 e relação glicemia / insulina < 6,4. O diagnóstico de IG e DM tipo 2 foi realizado por meio do teste de tolerância à glicose oral (TTGO) de acordo com os critérios do WHO, 1985 e comparado ao diagnóstico pela glicemia de jejum (ADA, 2003). Para a análise estatística dos resultados, foi utilizado o teste de qui-quadrado para a associação entre as variáveis, e para as variáveis quantitativas foram utilizadas a estatística descritiva e análise de variância seguida do método de Tukey ou t de student. As pacientes com SOP apresentaram idade entre 12 a 40 anos (24,8 ± 6,3) e índice de massa corpórea entre 18,3 a 54,9 Kg/m² (32,5 ± 7,6). O percentual de pacientes obesas foi de 64%. A RI foi detectada em 54,2% das pacientes pela relação glicemia / insulina, em 59,9% pelos índices de HOMA-IR e QUICKI, em 70,6% pelo ISI e 61,9% apresentaram insulinemia > 12 μIU/ml. A RI foi maior quanto... (Resumo completo, clicar acesso eletrônico abaixo)
Abstract: The polycystic ovary syndrome (PCOS) is a common endocrinopathy in women during menacme, with a prevalence ranging from 5 to 10%. In several studies, patients with PCOS have shown increased risk for developing glucose metabolism abnormalities. Diabetes mellitus is among the 10 major causes of mortality resulting from micro and macrovascular causes in Brazil. To evaluate the prevalence of insulin resistance (IR), impaired glucose tolerance (IGT) and type-2 diabetes mellitus (DM) in patients diagnosed with PCOS. The clinical, biochemical and ultrasonographic data of 247 patients diagnosed with PCOS were retrospectively analyzed. To compare IR levels, a group of 101 women with regular cycles without hyperandrogenism was used. IR diagnosis was performed by using the following cutoff values: insulinemia > 12 μIU/ml, HOMA-IR > 2.71, QUICK < 0.333, ISI < 4.75 and glycemia / insulin ratio < 6.4. The GI and type-2 DM diagnosis was performed by means of the oral glucose tolerance test (OGTT), according to WHO criteria, 1985 and compared with fasting plasma glucose diagnosis (ADA, 2003). The results were interpreted by the chisquare test for association between variables, and descriptive statistics and analysis of variance followed by Tukey's or Student's t tests were used for quantitative variables... (Complete abstract clic, electronic access below)
Mestre
APA, Harvard, Vancouver, ISO, and other styles
4

Patterson, Moneka Angilene. "Polycystic Ovary Syndrome Treatment." ScholarWorks, 2017. https://scholarworks.waldenu.edu/dissertations/4319.

Full text
Abstract:
Polycystic ovary syndrome (PCOS) is an endocrine system disorder that affects women of reproductive age. If not treated properly, PCOS can lead to infertility. Lack of proper treatment of PCOS may also result in medical complications such as diabetes or heart disease. The rural clinic where this project took place did not have a mandatory guideline for treatment of PCOS; therefore, no standardized method of diagnosis or treatment of PCOS existed. The purpose of this project, guided by the IOWA evidence-based practice model, was to educate providers on the evidence-based guideline for diagnosis and treatment of PCOS outlined by the Endocrine Society Taskforce. The guideline was selected after a comprehensive literature review and was used to develop an educational program that was provided to 5 nurse practitioners, the medical director and staff. A pre-test post-test design was used to determine if the participants understood the content from the guideline that was presented. Results showed that the researcher-developed test administered to participants yielded scores of 74 on the pre-test and increased after the education program with all participants scoring 100 on the post-test. The guideline used for the education was then presented to the clinic for implementation with the assistance of the medical director's support. The project provided an evidence-based guideline for diagnosing and treating PCOS and raised awareness of PCOS among all staff in a rural clinic where many patients with PCOS are treated. Positive social change may result as providers are better prepared to deliver evidence-based care for PCOS and as infertility and complications of untreated PCOS are reduced.
APA, Harvard, Vancouver, ISO, and other styles
5

Cho, Li Wei. "Cardiometabolic aspects of polycystic ovary syndrome." Thesis, University of Hull, 2008. http://hydra.hull.ac.uk/resources/hull:5826.

Full text
Abstract:
Polycystic ovary syndrome (PCOS) is a common endocrine disorder affecting 6-7% of the population. It is characterised by chronic anovulation and hyperandrogenism with the clinical manifestation of oligomenorrhoea, hirsutism and acne. A ten to twenty fold increased risk for type 2 diabetes in PCOS patients compared to weight matched female control subjects makes the syndrome of high socioeconomic importance. The use of differing diagnostic criteria makes the comparison of studies on PCOS difficult until harmonisation through the Rotterdam consensus in 2004. Despite being removed from the diagnostic criteria by the the Rotterdam consensus, the LH/FSH ratio is still widely used as one of the diagnostic criteria for PCOS. Therefore to determine the usefulness of the LH/FSH ratio in the diagnosis of PCOS, I have conducted a study as described in chapter two and showed that an elevated LH to FSH ratio was as commonly found in normal women as those with PCO, and therefore of no diagnostic value. In January 2004, the European Society for Human Reproduction and Embryology (ESHRE) and the American Society for Reproductive Medicine (ASRM) co-sponsored the Rotterdam polycystic ovary syndrome consensus workshop that published diagnostic guidelines, building on the consensus statement of the National Institutes of Health 1990. The Rotterdam criteria for the diagnosis of PCOS states 2 of the 3 features needs to be present to make the diagnosis, and with the exclusion of other aetiologies (congenital adrenal hyperplasia, androgen-secreting tumors, Gushing's syndrome). These features include (l)Oligo- or anovulation (2)Clinical and/or biochemical signs of hyperandrogenism and (3)Polycystic ovaries (either 12 or more follicles measuring 2-9 mm in diameter, or an ovarian volume of > 10 cm³ ). Following the introduction of this guideline, the diagnosis of PCOS in patients recruited for studies on PCOS have been standardised. However, the current biochemical test for hyperandrogenism in women is still not ideal, due to the variation in the assay at low values. All three of total testosterone, bioavailable testosterone and free androgen index (FAI) are currently used as markers of hyperandrogenism for the diagnosis of PCOS. In chapter three, I evaluated the variability of each of the three markers as well as their use in the diagnosis and monitoring patients with PCOS and found that FAI is a better diagnostic marker for hyperandrogenism in patients with PCOS, but once the diagnosis is made, all three methods are equally good in monitoring disease progression. It has now been recognised that the diagnosis of metabolic syndrome identifies patients at increased risk of developing cardiovascular disease, and attempts have been made to develop the most convenient and useful criteria for the diagnosis of this condition in clinical practice. With the pathogenesis of metabolic syndrome not well understood, central obesity and insulin resistance are acknowledged as important causative factors. Cardiovascular disease studies in PCOS had so far been inconclusive with some suggesting increased cardiac events among women with PCOS whilst other studies suggesting no increase compared with normal cycling women. This may be attributed to small sample size in studies and variation in characteristics of patients recruited as well as surrogate markers used. C-reactive protein (CRP) had been widely used as a marker of inflammation, endothelial dysfunction and risk of cardiovascular disease in general and in patients with PCOS. However, there had not been any studies on the biovailability of this marker as the potential utility of CRP as a marker of cardiovascular risk may be limited by the magnitude of this variability in both health and disease, since there can be substantial overlap between PCOS and control individuals. In chapter four, the biological variation of high sensitivity CRP in women with PCOS were compared to normal menstruating women. I found that while the mean concentration of CRP was higher in individuals with PCOS compared to healthy controls, the intraindividual variation of CRP was similarly large in both groups. Therefore, the potential utility of CRP as a marker of cardiovascular risk may be limited by the magnitude of this variability in both health and disease, since there can be substantial overlap between PCOS and control individuals. PCOS is associated with a high risk of progression to type 2 diabetes (T2DM) and impaired glucose tolerance. A history of T2DM in a first-degree relative appears to define a subset of PCOS subjects with a greater prevalence of insulin secretory defects. However, factors underlying the progression of PCOS to T2DM are unclear and may be due to either an increase in the underlying insulin resistance or the progression of beta cell failure. Chapter five described a comparison study between the insulin resistance and beta cell functions in patients with PCOS to that of diet controlled T2DM. I found that the progression from PCOS to the development of T2DM is unlikely to be due to a further increase in insulin resistance (or variability), but rather the progressive failure of pancreatic beta cells with a decrease in insulin production. Having established the effectiveness in the diagnosis of PCOS and its progression, I went on to establish the effectiveness of individual treatments of PCOS. The treatment of patients with PCOS requires that the specific goal(s) of the therapy be first established. Individual goals may include fertility, treatment for hirsutism and/or acne, achieving a regular menstrual cycle, weight reduction and the prevention of the long term consequences associated with PCOS (type 2 diabetes, dyslipidaemia and possibly cardiovascular disease) - or all of the above. Treatments aimed at modifying the long-term consequences on cardiometabolic aspect of PCOS include weight reduction strategies as well as the use of insulin sensitizers. There is currently insufficient data to suggest the superiority of one treatment over another or the use of these medications for treatment of cardiometabolic risks in patients with PCOS. Endothelial dysfunction had been recognised as an early marker for cardiovascular disease and chapter six compared the changes in endothelial function in women treated with either metformin or pioglitazone. I found that pioglitazone significantly improved endothelial function and hs-CRP whereas metformin did not produce significant improvements. Chapter seven evaluates the effects of orlistat, metformin and pioglitazone on metabolic profile and biological variability of IR in women with PCOS. The results showed that only orlistat reduced both IR and its variability significantly, though all three drugs were effective in reducing hyperandrogenism within the 12 week period of the study. These effects with orlistat were coupled with a significantly reduction in total cholesterol through a reduction in LDL. After conducting the above studies and searching through literatures, I found that studies in cardiometabolic risks in women with PCOS had so far shown conflicting results, and this may be due to the heterogeneity within the group. Chapter eight evaluates this heterogeneity particularly between anovulatory and ovulatory women with PCOS, where all subjects met the Rotterdam criteria. Women with anovulatory PCOS were found to have higher mean and biological variability of IR compared to those having an ovulatory cycle, and both were higher than women without PCOS. This suggests that the subset of patients who ovulate may be better protected against future cardiovascular consequences. In conclusion, this thesis demonstrated that LH/FSH ratio is of no use in the diagnosis of PCOS and that free androgen index appeared to be the best diagnostic marker when compared to total testosterone and bioavailable testosterone.
APA, Harvard, Vancouver, ISO, and other styles
6

Yasmin, Ephia. "Metabolic aspects of polycystic ovary syndrome." Thesis, University of Leeds, 2011. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.545722.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Baker, Elizabeth. "Illness Perceptions of Polycystic Ovary Syndrome." Scholar Commons, 2014. https://scholarcommons.usf.edu/etd/5176.

Full text
Abstract:
Polycystic ovary syndrome (PCOS) is a chronic illness that affects approximately five million premenopausal women in the United States and is associated with significant cosmetic, reproductive, metabolic, and psychological consequences. Despite its prevalence, few studies have explored the lived experiences and illness perceptions of women living with PCOS. Identifying illness perceptions of women living with (WLW) PCOS is important, because mounting research suggests that a person's perceptions of their chronic illness and its management determine that person's coping behaviors (e.g., adherence, self-management) and, consequently, illness outcomes. In this dissertation, the Common Sense Model (CSM) is used as a framework to identify the illness perceptions of PCOS held by WLW the syndrome. As such, this dissertation is the first to test the ecological validity of the CSM in a population of women diagnosed with PCOS. In addition, the relationship between illness perceptions and (1) infertility, a common symptom of the syndrome, and (2) health-related quality of life (HRQoL) is explored. Lastly, this study makes a novel contribution to the literature by describing one of the first samples of WLW PCOS recruited through a social networking site. This includes a discussion of the participant's demographic information, fertility experiences, and HRQoL. This is a two-phase mixed methods study. Phase one consisted of an online quantitative survey capturing data on 376 participants' demographic information and medical history. Data were also collected on each participant's HRQoL using the SF-36, a generic, well-validated measure of the phenomenon. Of the 376 survey participants, 34 were interviewed via phone or video chat in the fall 2013 and spring 2014 semesters. Quantitative data were downloaded from Qualtrics® and analyzed using SAS statistical software version 9.3. In this analysis, descriptive statistics were generated to describe sample characteristics and SF-36 domain scores were calculated for each participant. In the qualitative analysis, data were analyzed through a series of sorting techniques and transcripts were imported into NVivo 10 and subjected to content analysis. The mean age of survey participants was 31.8 years (SD=5.8). Respondents were primarily non-Hispanic (92.5%), white (88.3%), straight (94.4%), and married (73.4%) with a college education (64.1%). On average, participants reported living with PCOS for 7.6 years (SD=6.1). Approximately half of the sample reported having biological children (47.9%) and currently trying to conceive (42.1%), and most participants reported a history of infertility (70.7%). In addition, almost half of the total sample reported heights and weights that placed them in the morbidly obese category (BMI>35). Lastly, a history of depression (63.6%) and anxiety (68.6%) was common among participants. Few survey participants reported their general health as being excellent (2.6%) or very good (27.4%). Similarly, women reported the lowest levels of functioning on the dimension of vitality, meaning that, in general, women reported feeling tired and being low in energy. Conversely, women reported the highest scores on the dimensions of physical functioning and role limitations due to physical health, meaning that, in general, women did not report that their health limited their physical abilities or caused problems with work or other daily activities. Interview findings suggest that WLW PCOS generally have illness perceptions of the syndrome that are consistent with the domains identified in the CSM. In addition, it was found that, in relation to their illness cognitions, WLW PCOS described the extent to which they felt they had a comprehensive understanding of the syndrome, a phenomenon labeled illness coherence. Similarly, participants identified PCOS as a common condition (i.e. labeled perceived prevalence). Lastly, a number of relationships were identified between illness perceptions and (1) infertility status and (2) HRQoL scores. Overall, this dissertation identifies a number of implications for patient education, provider education, clinical practice, and policy improvements. Examples include addressing (1) unmet information needs, (2) significant psychological morbidity and unmet mental health needs, (3) breastfeeding challenges and need for breastfeeding support, (4) poor quality of care and low patient satisfaction, and (5) limited access to care - all among women living with PCOS.
APA, Harvard, Vancouver, ISO, and other styles
8

Morin-Papunen, L. (Laure). "Insulin resistance in polycystic ovary syndrome." Doctoral thesis, University of Oulu, 2000. http://urn.fi/urn:isbn:9514257405.

Full text
Abstract:
Abstract The polycystic ovary syndrome, described first as the association of bilateral polycystic ovaries and amenorrhoea, oligomenorrhoea, hirsutism and obesity, was later shown to be a complex metabolic syndrome. The first purpose of this study was to investigate the occurrence of hyperinsulinaemia and the severity of insulin resistance and glucose tolerance disorders in polycystic ovary syndrome by means of the oral glucose tolerance test and the euglycaemic hyperinsulinaemic clamp. The next goal was to investigate whether women with polycystic ovary syndrome would benefit from insulin-sensitising drugs, and in particular to compare the effects of metformin and a contraceptive pill containing ethinyl oestradiol and cyproterone acetate. Altogether, 81 women with polycystic ovary syndrome and 34 healthy control subjects were involved in the study. Marked impairment of insulin sensitivity in obese subjects with polycystic ovary syndrome, including a decrease of both cellular oxidative and non-oxidative utilisation of glucose, and a slight non-significant decrease of insulin sensitivity in non-obese subjects was observed. Both non-obese and obese subjects with polycystic ovary syndrome exhibited increased abdominal obesity compared with the controls, confirming the fact that obesity, in particular abdominal obesity, is an important contributor in the development of insulin resistance in this syndrome. Metformin alleviated hyperandrogenism by essentially decreasing ovarian, but not adrenal androgen secretion. The improvement of hyperandrogenism and ovarian function seemed to be mediated by the improvement of hyperinsulinaemia, which resulted itself from subtle improvements in both hepatic insulin extraction and insulin sensitivity. Metformin decreased abdominal obesity and the release of free fatty acids from adipose tissue, and improved ovarian cyclicity and fertility. The transient decrease in serum leptin levels observed may have some role in the improvement of ovarian function. The contraceptive pill significantly improved hyperandrogenism and hirsutism, and it slightly affected glucose metabolism. Thus, it could be the treatment of choice in women with hirsutism problems and no fertility hopes. Metformin could be the drug of choice for women with polycystic ovary syndrome who wish to conceive. Because of its beneficial metabolic effects, the value of metformin in reducing the risk of cardiovascular diseases in polycystic ovary syndrome needs to be further studied.
APA, Harvard, Vancouver, ISO, and other styles
9

Lindholm, Åsa Maria. "Metabolic Aspects in the Polycystic Ovary Syndrome." Doctoral thesis, Uppsala universitet, Institutionen för kvinnors och barns hälsa, 2010. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-120235.

Full text
Abstract:
Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders among women of childbearing age and is associated with a number of metabolic disturbances. It has been hypothesised these women carry an increased risk of developing cardiovascular diseases (CVD) with advancing age. The first aim of this thesis was to establish the prevalence of PCOS-related symptoms in Northern Sweden. The Northern part of the WHO MONICA project was used for this purpose. Based on self-reported menstrual disturbances and hirsutism together with biochemical analyses of free androgen index, the estimated prevalence of PCOS in Northern Sweden was 4.8%, which corresponded with previous prevalence studies. Disturbances in the fibrinolytic system are predictors of future cardiovascular events and measurements of plasminogen activator inhibitor 1 (PAI-1) activity and tissue plasminogen activator (tPA) mass concentration may be used to assess fibrinolytic activity in women with PCOS. From the findings, over-weight women with PCOS had impaired fibrinolysis, especially if they displayed objective biochemical markers of hyperandrogenism. Conversely, lean women with PCOS, displayed no signs of disturbed fibrinolysis. The adipose tissue is an active endocrine organ that produces and releases hormones, pro- and anti-inflammatory cytokines, and chemoattractant cytokines. Proinflammatory molecules produced by adipose tissue can be active participants in the development of insulin resistance and the increased risk of cardiovascular disease associated with obesity. The findings suggested being overweight, rather than the PCOS diagnosis per se, was the main explanatory variable for elevated adipose tissue inflammation in PCOS patients. Weight reduction is the primary target for intervention in overweight and obese women with PCOS. When this thesis was planned, no placebo-controlled trials on anti-obesity drugs in women with PCOS had been conducted. Sibutramine in combination with lifestyle intervention resulted in significant weight reduction in overweight women with PCOS. In addition to the weight loss, sibutramine appeared to have a beneficial effect on metabolic and cardiovascular risk factors.
APA, Harvard, Vancouver, ISO, and other styles
10

Lindholm, Åsa Maria. "Metabolic Aspects in the Polycystic Ovary Syndrome." Uppsala : Acta Universitatis Upsaliensis : Univ.-bibl. [distributör], 2010. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-120235.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Polycystic ovary syndrome. eng"

1

Elsheikh, Mohgah. Polycystic ovary syndrome. Oxford: Oxford University Press, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Dunaif, Andrea, R. Jeffrey Chang, Stephen Franks, and Richard S. Legro, eds. Polycystic Ovary Syndrome. Totowa, NJ: Humana Press, 2008. http://dx.doi.org/10.1007/978-1-59745-108-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Chang, R. Jeffrey, ed. Polycystic Ovary Syndrome. New York, NY: Springer New York, 1996. http://dx.doi.org/10.1007/978-1-4613-8483-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

HOMBURG, ROY, and MB BS. Polycystic Ovary Syndrome. Abingdon, UK: Taylor & Francis, 1988. http://dx.doi.org/10.4324/9780203426708.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Pal, Lubna, ed. Polycystic Ovary Syndrome. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4614-8394-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Polycystic ovary syndrome. New York: Rosen Central, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Elsheikh, Mohgah. Polycystic ovary syndrome. Oxford: Oxford University Press, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

1970-, Sterling Evelina Weidman, and Goldstein Jerald S. 1965-, eds. Living with PCOS: Polycystic ovary syndrome. 2nd ed. Omaha, Neb: Addicus Books, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Best-Boss, Angie. Living with PCOS: Polycystic ovary syndrome. 2nd ed. Omaha, Neb: Addicus Books, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Best-Boss, Angie. Living with PCOS: Polycystic ovary syndrome. 2nd ed. Omaha, Neb: Addicus Books, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Polycystic ovary syndrome. eng"

1

Balen, Adam. "Polycystic Ovary Versus Polycystic Ovary Syndrome." In Polycystic Ovary Syndrome, 37–49. Totowa, NJ: Humana Press, 2008. http://dx.doi.org/10.1007/978-1-59745-108-6_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Sood, Minisha, Susan B. Zweig, Marsha C. Tolentino, Marina Strizhevsky, and Leonid Poretsky. "Polycystic Ovary Syndrome." In Principles of Diabetes Mellitus, 659–77. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-18741-9_33.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Wheeler, Catherine J., William R. Keye, and C. Matthew Peterson. "Polycystic Ovary Syndrome." In Reproductive Endocrinology and Infertility, 147–82. New York, NY: Springer New York, 2010. http://dx.doi.org/10.1007/978-1-4419-1436-1_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Rosenblum, Jennifer, and Laya Ekhlaspour. "Polycystic Ovary Syndrome." In The MassGeneral Hospital for Children Adolescent Medicine Handbook, 187–93. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-45778-9_18.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Sattar, Naveed. "Polycystic Ovary Syndrome." In The Metabolic Syndrome, 278–96. Oxford, UK: Wiley-Blackwell, 2011. http://dx.doi.org/10.1002/9781444347319.ch16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Zweig, Susan B., Marsha C. Tolentino, Marina Strizhevsky, and Leonid Poretsky. "Polycystic Ovary Syndrome." In Principles of Diabetes Mellitus, 515–30. Boston, MA: Springer US, 2009. http://dx.doi.org/10.1007/978-0-387-09841-8_33.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Pfeifer, Samantha M. "Polycystic Ovary Syndrome." In Practical Pediatric and Adolescent Gynecology, 355–60. Oxford, UK: Blackwell Publishing Ltd., 2013. http://dx.doi.org/10.1002/9781118538555.ch50.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Kirby, Joslyn. "Polycystic Ovary Syndrome." In Acneiform Eruptions in Dermatology, 149–54. New York, NY: Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4614-8344-1_21.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Sattar, Naveed, and Richard Fleming. "Polycystic Ovary Syndrome." In The Metabolic Syndrome, 305–32. Chichester, UK: John Wiley & Sons, Ltd, 2006. http://dx.doi.org/10.1002/0470025131.ch12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Rosenblum, Jennifer. "Polycystic Ovary Syndrome." In The MassGeneral Hospital for Children Adolescent Medicine Handbook, 115–18. New York, NY: Springer New York, 2010. http://dx.doi.org/10.1007/978-1-4419-6845-6_16.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Polycystic ovary syndrome. eng"

1

Mehrotra, Palak, Chandan Chakraborty, Biswanath Ghoshdastidar, Sudarshan Ghoshdastidar, and Kakoli Ghoshdastidar. "Automated ovarian follicle recognition for Polycystic Ovary Syndrome." In 2011 IEEE International Conference on Image Information Processing (ICIIP). IEEE, 2011. http://dx.doi.org/10.1109/iciip.2011.6108968.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

do Vale, Jessica, Adriana Maria Wan Stadnik, and Frieda Saicla Barros. "FAT DISTRIBUTION IN WOMEN WITH POLYCYSTIC OVARY SYNDROME." In XI Simpósio de Engenharia Biomédica. Uberlândia, Minas Gerais: Even3, 2018. http://dx.doi.org/10.29327/xiseb.128378.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Yinhui Deng, Yuanyuan Wang, and Ping Chen. "Automated detection of Polycystic Ovary Syndrome from ultrasound images." In 2008 30th Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE, 2008. http://dx.doi.org/10.1109/iembs.2008.4650280.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Bharati, Subrato, Prajoy Podder, and M. Rubaiyat Hossain Mondal. "Diagnosis of Polycystic Ovary Syndrome Using Machine Learning Algorithms." In 2020 IEEE Region 10 Symposium (TENSYMP). IEEE, 2020. http://dx.doi.org/10.1109/tensymp50017.2020.9230932.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Mehrotra, Palak, Jyotirmoy Chatterjee, Chandan Chakraborty, Biswanath Ghoshdastidar, and Sudarshan Ghoshdastidar. "Automated screening of Polycystic Ovary Syndrome using machine learning techniques." In 2011 Annual IEEE India Conference (INDICON). IEEE, 2011. http://dx.doi.org/10.1109/indcon.2011.6139331.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Idacahyati, Keni, Tita Nofianti, and Ema Sintya Nurjaya. "Evaluation of Label Drug in the Treatment Polycystic Ovary Syndrome." In 2nd Bakti Tunas Husada-Health Science International Conference (BTH-HSIC 2019). Paris, France: Atlantis Press, 2020. http://dx.doi.org/10.2991/ahsr.k.200523.032.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

van der Plaat, Diana, Cosetta Minelli, Deborah Jarvis, Judith Garcia-Aymerich, Francisco Gomez-Real, and Bénédicte Leynaert. "Polycystic ovary syndrome and lung function: a Mendelian randomization study." In ERS International Congress 2019 abstracts. European Respiratory Society, 2019. http://dx.doi.org/10.1183/13993003.congress-2019.pa5390.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Hong Ma, Xiaohong Quan, Jianwei Li, Bin, and Xiuhua Chen. "Acupuncture for polycystic ovary syndrome: A systematic review and meta-analysis." In 2014 IEEE Workshop on Electronics, Computer and Applications (IWECA). IEEE, 2014. http://dx.doi.org/10.1109/iweca.2014.6845743.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

"An overview of effective herbs in the treatment of polycystic ovary syndrome." In International Conference on Medicine, Public Health and Biological Sciences. CASRP Publishing Company, Ltd. Uk, 2016. http://dx.doi.org/10.18869/mphbs.2016.93.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Hosseinkhani, A., N. Asadi, M. Pasalar, and M. Zarshenas Mohammad. "Insights of traditional Persian medicine to polycystic ovary syndrome and its management." In GA 2017 – Book of Abstracts. Georg Thieme Verlag KG, 2017. http://dx.doi.org/10.1055/s-0037-1608536.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Polycystic ovary syndrome. eng"

1

Yang, Yijiao, Honglin Liu, Yue Xia, Xia Peng, and Xiaorong Ni. Tanshinone for polycystic ovary syndrome: a protocol of systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, October 2020. http://dx.doi.org/10.37766/inplasy2020.10.0017.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Wang, Yuanyuan, Zhaoning Duan, Yunpeng Wang, Xiwen He, and Zhi Cheng. Association between the CYP17A1 − 34T/C polymorphism and polycystic ovary syndrome: A meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, November 2020. http://dx.doi.org/10.37766/inplasy2020.11.0081.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Pan, Jing, Jianwei Zhang, Shan Xiang, Shangqian Dong, and Xiuyun Qin. A comparison of the efficacy and safety of complementary and alternative therapies for Polycystic Ovary Syndrome. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, January 2021. http://dx.doi.org/10.37766/inplasy2021.1.0077.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Xu, Kou, Zhongyu Zhou, Wei Huang, Siying Lv, Yanji Zhang, and Chen Wan. Effectiveness and safety of moxibustion treatment for Polycystic Ovary Syndrome: a protocol for systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, November 2020. http://dx.doi.org/10.37766/inplasy2020.11.0049.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Miao, Chenyun, Qingge Guo, Xiaojie Fang, Yun Chen, Ying Zhao, and Qin Zhang. Effects of Probiotics and Synbiotics Supplementation on Insulin Resistance in Women with Polycystic Ovary Syndrome: A Meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, May 2021. http://dx.doi.org/10.37766/inplasy2021.5.0112.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Lei, Wenwen, Yang Gao, Shiruo Hu, Dongyin Liu, and Qiu Chen. Effects of inositol and alpha lipoic acid combination for polycystic ovary syndrome: a protocol for systematic review and meta-analysis. International Platform of Registered Systematic Review and Meta-analysis Protocols, May 2020. http://dx.doi.org/10.37766/inplasy2020.5.0011.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Geng, Jingran, Jinmeng Lv, Shuancheng Zhang, Yucong Ma, Xiao Liang, Ying Sun, and Huilan Du. Efficacy and safety of acupuncture for Polycystic Ovary Syndrome undergoing in vitro fertilization：A protocol for systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, February 2021. http://dx.doi.org/10.37766/inplasy2021.2.0069.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Ye, Wenguo, Gen Deng, Lin Yin, and Jing Ye. Efficacy and safety of moxibustion in the treatment of infertility with polycystic ovary syndrome: a protocol of systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, January 2021. http://dx.doi.org/10.37766/inplasy2021.1.0004.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Feng, Jing, Xiao-feng Zhang, Jie-ning Ren, Yu-hua Huang, and Xin Zheng. Efficacy of clomifene citrate combined Bushen Culuan Decoction for the treatment of infertility caused by polycystic ovary syndrome: a protocol of systematic review. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, May 2020. http://dx.doi.org/10.37766/inplasy2020.5.0090.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Shi, Xiaoyan, Jia Yao, Simin Fan, and Qiu Chen. Effects of Vitamin D Supplementation on Serum Lipid Profile in Women with Polycystic Ovary Syndrome: A protocol for a systematic review and Meta-analysis. International Platform of Registered Systematic Review and Meta-analysis Protocols, May 2020. http://dx.doi.org/10.37766/inplasy2020.5.0007.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Polycystic ovary syndrome. eng' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography